ArticleEuropean journal of clinical pharmacology2006
Effects of atorvastatin on higher functions.
Article in European journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01186289 (Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The effects of cholesterol-lowering drugs on neurocognitive function: systematic review and meta analysis.Frontiers in neurologyPooled it
- Trial
- Trial
- Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases.Frontiers in neurology · 2025Article
- Current drug treatment of hyperlipidemia in older adults.Drugs & aging · 2015Review
- Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.Drug safety · 2014Article
- Cognitive effects of statin medications.CNS drugs · 2014Review
- Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.CNS drugs · 2014Review
- Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins?Current atherosclerosis reports · 2013Review
- A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion.Neuropsychiatric disease and treatment · 2013Article
- Reversible dysphasia and statins.Journal of Korean medical science · 2012Article
- Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats.Psychopharmacology · 2011Article
- The effects of cholesterol on learning and memory.Neuroscience and biobehavioral reviews · 2010Review
- Promoting successful cognitive aging: a comprehensive review.Journal of Alzheimer's disease : JAD · 2010Review
- Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.Drugs & aging · 2009Review
- Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.Drug safety · 2008Article
- On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.
methodsIn this before and after comparison study with controls, group one included 55 subjects aged > or =40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores.
resultsBoth subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38-0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09-0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22-0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93-1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36-0.82, p<0.05).
conclusionThe present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.